Fuente: FierceBiotech The FDA has put a partial clinical hold on PepGen’s phase 2 muscle wasting trial after reviewing preclinical data, continuing the stop-start advance of the program. Guggenheim Securities analysts blamed the hold on an “understaffed FDA.”